ClinicalTrials.gg
RecruitingNCT07142447CONTINUEUpdated Aug 26, 2025

Effectiveness of a multicOmpoNent Behavioural intervenTion to Reduce endocrINe disrUptor Exposure During pErinatal Period (CONTINUE)

An interventional study of Multi-Component Behavioral intervention and Control group in Pregnancy and Children, sponsored by Fundació Institut Germans Trias i Pujol. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Fundació Institut Germans Trias i Pujol · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Feb 2025, registered Jul 2025).
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The general objective of HYPIEND is to understand the effects of chemical substances called "endocrine disruptors" (EDCs) during the perinatal and pre-pubertal stages. EDCs co-exposure may affect the function of hormones and determine endocrine consequences in vulnerable populations.

The primary objective of this clinical study is to demonstrate that a multicomponent intervention implemented in health care centres from three European countries is effective in reducing the levels of EDCs in different body fluids of pregnant women, breastfeeding and formula feeding women as well as in their infants up to 18 months of age, improving at the same time the level of HAPA constructs (psychological determinants of behaviour) and the knowledge about these chemicals at family level.

Read the detailed description

Study rationale

  1. Extent and evaluation of current knowledge directly linked to the scientific question(s) to be answered by the clinical study.

    Human epidemiological data suggest that EDC exposure during the perinatal period can negatively affect infant growth trajectory and neurodevelopment and possibly play an important role in the rapid epidemiological growth of obesity and diabetes. As an example, one study carried out in 460 mother-infant pairs from Korea showed that Mental and/or Psychomotor Developmental Indices of the Bayley Scales of Infant Development were inversely correlated in 6-month-old males with the maternal urinary levels of the phthalate metabolites MEHHP, MEOHP and MBP at the third trimester of pregnancy. Very recently, it was reported that mothers with overweight displayed increased levels of the highly persistent environmental chemicals polychlorinated biphenyls in breast milk 2-weeks postpartum and that there was a negative association between some of these compounds and the head circumference-for-age, weight-for-age, and weight-for-length z-scores of the infant at the age of 6 months.

    However, there are discrepancies among findings, which can be attributed to differences in the temporal window of EDC exposure assessment (i.e., early versus late gestation or lactation), in the infants' age at which the measurements were carried out or to a misclassification of EDC exposure due to a single-point analyses of their exposure. In fact, one of the limitations of many epidemiological studies is the use of single spot urine samples at one time-point to estimate the exposure to EDCs. The limitation relies on the short biological half-lives of many of these chemicals and their quick excretion in urine, properties that cause a demand for multiple time point for a precise estimation of exposure assessment. Although different epidemiological studies have found an association between higher exposure to EDCs and neuroendocrine and neurodevelopmental alterations in toddlers and children, as far as we know, no clinical interventions have been carried out to elucidate whether reducing the exposure to EDCs can contribute to counteract/ameliorate these harmful effects.

    So far, very few human intervention studies focused on reducing the exposure to EDCs during the perinatal period have been conducted, some carrying out educational approaches and others focused on dietary or other changes. Relevantly, most of them had small sample sizes (\<100 people) and analysed a maximum of two different types of EDCs and quite a few were carried out without control groups. Moreover, the level of adherence in this type of interventions is low in general, reflecting the need to implement adequately behavioural change techniques to foster long-term lifestyle habit improvements.

  2. Outcomes (efficacy, safety) Of completed and number of ongoing clinical studies utilizing the same intervention in the same indication (including review of public registers)

    Recently, the PREVED project was carried out to improve knowledge, to enhance risk perception and to change exposure behaviour regarding EDCs of 268 women during pregnancy and up to 14 months after birth . The authors reported a significant increase in the evolution of risk perception score and overall psychosocial score in the two intervention groups that received 3 workshops during pregnancy, one group in neutral location (leaflet on EDCs and collective workshops in a meeting room), and the other group in contextualized location (leaflet on EDCs and collective workshops in the real-life pedagogical apartment) when compared with a control group (leaflet on EDCs). However, no differences in consumption of canned food and in percentage of women having a decrease in bisphenol A or parabens concentrations in urine were found between the control and the two intervention groups. In another RCT carried out in 51 women in Korea, a 4-week web-based behavioural intervention reduced the urinary concentrations of BPA, different phthalate metabolites, and parabens in mothers with young children . Moreover, an ongoing study aims to determine if a personalized mobile intervention is able to reduce the exposure to EDCs in adults of child-bearing age (ClinicalTrials ID: NCT05780047). Despite some promising results, these examples illustrate the need to carry out larger multicomponent clinical and community-based intervention studies focused on minimize the exposure to EDCs at short, medium, and long time to obtain results that are more conclusive.

  3. Level of evidence related to the mechanism of action of the intervention in the planned clinical study population

EDC-Mix-Risk and ENDpoiNTs are two outstanding Horizon 2020 projects that combined the experimental research in both cells and animals with epidemiological data. Researchers of both projects and others nicely showed using a statistical model for multivariate regression with data obtained in the SELMA pregnancy study that different EDCs (including phthalates, alkyl phenols, and perfluoroalkyl substances) analysed in the urine and serum of women at week 10 of pregnancy were associated with language delay of their children at 2.5 years of age. Afterwards, the identified EDCs were mixed and tested in human brain organoids as well as in Xenopus leavis and Danio rerio to elucidate the molecular and functional impact of exposure. Finally, the authors integrated both experimental and epidemiological data and carried out a risk assessment approach, finding increased odds of language delay in up to 54% of the offspring who had prenatal exposures above experimentally derived levels of concern: Despite these very relevant findings, a limited number of studies carried out in humans have shed light on the mechanisms underlying the EDC-mediated dysfunctions on HP axis, including the induction of epigenetic changes in key genes involved in foetal development, neuroendocrine regulation and early puberty as well as the alterations of the inflammatory response and the gut microbiota (dysbiosis). EDCs may increase the risk of childhood neurodevelopmental disorders by interfering with early life estrogenic and thyroid hormone signalling or metabolism. In this sense, in humans, it has been shown that some phthalates may reduce thyroxine and triiodothyronine concentration in pregnant women and children and that the exposure to phthalates produced oxidative stress and can also affect the health of the offspring through epigenetic re-programming of the foetus and placenta. In another study, maternal exposure to heavy metals affected progeny neurodevelopment, and changes in DNA methylation of genes controlling neurodevelopment were observed in cord blood, but not the blood collected at mid-childhood. Analysis of exposure-outcome identified differentially methylated CpG on DAB Adaptor Protein 1 (DAB1) gene as a marker of the effect of prenatal polycyclic aromatic hydrocarbon (PAH) exposure on children's mental development. Increased exposure to PAHs during pregnancy was positively correlated with the methylation of insulin-like growth factor IGF1 and 2, key factors in human growth and development that are maternally imprinted. Incorrect methylation of those genes during early development relates to reduced birth weight and increased predisposition to metabolic problems, like obesity, cardiovascular diseases or diabetes. However, despite this evidence, as far as we know, no human intervention studies aimed at reducing the exposure to EDCs have analysed the molecular impact that can accompany these changes in EDC exposure. Further research is needed to shed more light on these issues, including molecular and omics-based analyses in humans to elucidate whether human intervention studies aimed at reducing EDC exposure can favourably modulate these molecular changes.

Different molecular and omics approaches will be carried out to shed more light in the framework of the HP axis on the epigenetic drivers most susceptible to disruption, the genes and the pathways most differently affected, the interplay between intestinal microbiota and the impact of EDC exposure on systemic inflammation. These analyses will be carried out in samples obtained in the study considering our results obtained in preclinical models exposed to EDC mixtures trying to resemble the real human exposure, to increase the chance to obtain robust and reliable results using a targeted approach. Specifically, in women the analyses will be carried out during pregnancy and after delivery at different time points and will be focused on the analyses of HP axis-related hormones and cytokines, intestinal microbiota, methylation of different CpG sites of key genes involved in HP axis as well as the expression of these genes. In their offspring, in addition to these analyses, the circulating levels of kisspeptin will be also analysed at birth (cord blood) and at the age of 18 months (capillary blood/dry blood spots -DBS-). Overall, these analyses will allow us to go into depth on the mechanisms by which EDCs exert their harmful effects as well as how intervention studies aimed at reducing the exposure to these chemicals can modulate these biological pathways and the molecular biomarkers of exposure identified. As far as we know, this approach has not yet been carried out in large human intervention studies in the framework of EDCs.

02

Conditions studied

  • Pregnancy
  • Children

Keywords

  • Endocrine Disruptors
  • hormones
03

In context

Lead sponsor

Fundació Institut Germans Trias i Pujol is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women with a viable pregnancy confirmed by ultrasound until 13 weeks and 0 days of gestation (recruitment between 6-11 weeks). Their partners will be invited to participate but this is not mandatory for inclusion.
  • at Visit 1 between 18.5-40 kg/m²
  • Intention to breastfeed
  • Being able to read the language of their respective countries (Dutch/French -Belgium-, Spanish and/or Catalan -Spain- and Polish -Poland)
  • Being 18 years or older
  • In possession of a smartphone. If participants do not have a smartphone because of socio-economic reasons, a smartphone will be at their disposal for the whole duration of the study

Exclusion criteria

Exclusion Criteria:

  • Unable to sign (cultural barriers, psychological conditions)
  • Abuse of substances (alcohol, drugs)
  • Chronic use (at least, for three months before pregnancy) of any medication that might affect the HP axis:
  • Antidepressants
  • Insuline.
  • Levothyroxine, Methimazole, Propylthiouracil.
  • Oral (topical and inhalation formulations will be allowed)
  • Arginine vasopressin (AVP)
  • Mifepristone.
  • Anticortisolic drugs: Metyrapone (Metopirone), Ketokonazole, Osilodrostat (Isturisa), Mitotane (Lysodren), aminoglutethimide (Cytadren) and Levoketoconazole (Recorlev).
  • Multiple gestation
  • Type 1 or 2 diabetes
  • Pregnant women will not be consented into research by any HCP with whom they have a dependent relationship (Declaration of Helsinki) (I would remove this point).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
810 participants (estimated)

Study arms

  • Experimental
    Behavioral intervention

    Healthy pregnant women who will receive a multi-component behavioral intervention (digital tool aimed at promoting lifestyle habits to reduce EDC exposure by providing personalized recommendations + telephone monitoring + workshops about environmental health education) during pregnancy and the first 18 months after delivery.

    Behavioral: Multi-Component Behavioral intervention

  • Other
    Control group

    Healthy pregnant women who will receive the standard of care. The control condition consists of a single online education module/written information about EDCs addressed to reduce their exposure. They will also have access to the digital tool to answer the questionnaires, but this group will not receive any recommendations or missions from the professionals concerning EDCs along the study. After finishing the intervention, the participants of the control group will be offered access to all the developed material (workshops…) and to use the app.

    Behavioral: Control group

Interventions

  • BehavioralMulti-Component Behavioral intervention

    A multicomponent behavioral intervention during pregnancy and up to the first 18 months after delivery, composed by: 1. Digital tool called "App Hypiend Digital Tool" aimed at promoting lifestyle habits to reduce EDC exposure by providing personalized recommendations 2. Telephone monitoring 3. Workshop about environmental health education

  • BehavioralControl group

    Minimal behavioral intervention. Usual care

    Also known as: Minimal behavioral intervention. Usual care

06

What researchers measure

Primary outcomes

  1. Decrease of mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) concentration in urine

    This election was based on a scientific article in which was reported that mental and/or Psychomotor Developmental Indices of the Bayley Scales of Infant Development were inversely correlated in 6-month-old infants with the maternal urinary levels of MEHHP and MEOHP at the third trimester of pregnancy in a study carried out with 460 mother-infant pairs (4). However, since during the initial phase of the project a predictive modelling approach will be carried out in order to select the EDC mixtures with high harmful effects to be evaluated in preclinical models, the definitive main outcome could be redefined once we obtain the predictive modelling results. We would expect to detect a 25% decrease in the urinary levels of MEOHP in the intervention group vs control group at the end of the study.

    Time frame: From first trimester of pregnancy to 18 months after delivery

Other outcomes

  1. Reduction of EDC levels in biological fluids

    Other EDCs in urine, peripheral blood, cord blood and milk

    Time frame: From first trimester of pregnancy to 18 months after delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Schulz MC, Sargis RM. Inappropriately sweet: Environmental endocrine-disrupting chemicals and the diabetes pandemic. Adv Pharmacol. 2021;92:419-456. doi: 10.1016/bs.apha.2021.04.002. Epub 2021 Jun 9. PubMed 34452693 ↗
  • Heindel JJ, Howard S, Agay-Shay K, Arrebola JP, Audouze K, Babin PJ, Barouki R, Bansal A, Blanc E, Cave MC, Chatterjee S, Chevalier N, Choudhury M, Collier D, Connolly L, Coumoul X, Garruti G, Gilbertson M, Hoepner LA, Holloway AC, Howell G 3rd, Kassotis CD, Kay MK, Kim MJ, Lagadic-Gossmann D, Langouet S, Legrand A, Li Z, Le Mentec H, Lind L, Monica Lind P, Lustig RH, Martin-Chouly C, Munic Kos V, Podechard N, Roepke TA, Sargis RM, Starling A, Tomlinson CR, Touma C, Vondracek J, Vom Saal F, Blumberg B. Obesity II: Establishing causal links between chemical exposures and obesity. Biochem Pharmacol. 2022 May;199:115015. doi: 10.1016/j.bcp.2022.115015. Epub 2022 Apr 5. PubMed 35395240 ↗
  • O'Shaughnessy KL, Fischer F, Zenclussen AC. Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children. Best Pract Res Clin Endocrinol Metab. 2021 Sep;35(5):101568. doi: 10.1016/j.beem.2021.101568. Epub 2021 Sep 4. PubMed 34565681 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — All data will be treated confidentially, and privacy of all participants will be protected by saving personal data separately from research data on encrypted files with identification numbers that can only be accessed by the main researchers working on this project. The file containing personal data will be destroyed after data collection has been completed. Data about the usage of the application will not contain IP address information and therefore it cannot directly identify its user and related personal information. Data management and agreements to transfer data/samples is dealt in a Data Protection Impact Assessment.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 26, 2025
StartActual
Feb 24, 2025
Primary completionEst.
Jan 2026
CompletionEst.
Jul 2027
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142447
Lead sponsor
Fundació Institut Germans Trias i Pujol
Collaborators
KU Leuven, Universidad de Granada, Fundació Eurecat
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Feb 24, 2025
Primary completion
Jan 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 26, 2025

Study contacts

Inés Velasco, MD, PhD
Contact
ivelasco@igtp.cat
+ 34 696914449
Magí Farré, MD, PhD
Contact
mfarre.germanstrias@gencat.cat
+34 93 497 89 74
Inés Velasco, MD, PhD
principal investigator · Foundation Institute of Research in Health Sciences Germans Trias i Pujol

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion